QRxPharma Ltd. (QRX) failed to win the backing of U.S. regulatory advisers for its painkiller that combines two opioids in an attempt to reduce side effects.
The experimental drug Moxduo shouldn’t be approved and doesn’t provide enhanced safety compared with the opioids alone, a Food and Drug Administration advisory panel voted unanimously today. Moxduo combines morphine and oxycodone. If approved, the medicine would be the first combination pill with two opioids.
Help employers find you! Check out all the jobs and post your resume.
